IVERIC bio Announces Publication of GATHER1 Phase 3 Clinical Trial Results for Zimura® in Geographic Atrophy Secondary to Age-related Macular Degeneration, in Ophthalmology®, the Journal of the American Academy of Ophthalmology
About IVERIC bio, Inc.
- NASDAQ: $ISEE
- Notified: $4.83
- 08:46 EDT